Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
Authors
William Tillett (ORCID: https://orcid.org/0000-0001-7531-4125)
Barbara Ink
M. Elaine Husni (ORCID: https://orcid.org/0000-0002-3181-4205)
Jason Coarse
Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
Dafna D. Gladman (ORCID: https://orcid.org/0000-0002-9074-0592)
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
William Tillett, Barbara Ink, M. Elaine Husni, Jason Coarse et al.
Citations
3 citations
Journal
RMD Open
Topics
Spondyloarthritis Studies and Treatments
Field-Weighted Citation Impact (FWCI)
1.41
article
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
William Tillett, Barbara Ink, M. Elaine Husni, Jason Coarse, Joseph Frank Merola, Dafna D. Gladman, Jérémy Lambert, V. Taieb, Philip J. Mease, Nadine Goldammer
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
RMD OpenVol. 10(3)
Institutions
Brigham and Women's Hospital (US), Royal National Hospital for Rheumatic Diseases (GB), Cleveland Clinic (US), University Health Network (CA), Harvard University (US), University of Toronto (CA), Toronto Western Hospital (CA), Cleveland Clinic Lerner College of Medicine (US), Swedish Medical Center (US), UCB Pharma (France) (FR), UCB Pharma (Germany) (DE), Krembil Research Institute, University of Bath (GB)